Vivos Therapeutics, Inc. (VVOS)

Market Closed

17 Jul, 20:00

NASDAQ (CM)

0. 42

+0.01

+1.6949%

2.41M Market Cap

- P/E Ratio

- Div Yield

131,500 Volume

-3.4 Eps

$ 0.41

Previous Close

Investors:

Analysts:

Add Transaction

Day Range

0.39 0.42

Year Range

0.38 6.46

Want to track VVOS and more in your Portfolio? 🎯

Get Started For Free

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call.

Seekingalpha | 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Incorporated Operator Good day, everyone, and welcome to the Vivos Second Quarter 2024 Earnings Conference Call. [Operator Instructions] This conference is being recorded, and a replay of today's call will be available in Investor Relations section of Vivos' website and will be remaining posted there for the next 30 days.

Seekingalpha | 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics First Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.

Seekingalpha | 2 years ago

Blog Affiliate Program About Terms Privacy Help Contact Us